Brief: Pluristem Therapeutics Gets Approval To Enroll Final Cohort In Phase I Hematological Study Of PLX-R18

Pluri

12/03/2019 12:29

March 12 (Reuters) - Pluristem Therapeutics Inc  PSTI.O :
    * PLURISTEM THERAPEUTICS ANNOUNCES COMPLETION OF 2ND COHORT
AND
DSMB APPROVAL TO ENROLL FINAL COHORT IN PHASE I HEMATOLOGICAL
STUDY OF PLX-R18
    * PLURISTEM - RESULTS FROM FIRST TWO COHORTS DEMONSTRATE
PLX-R18
IS SAFE AND WELL TOLERATED, WITH EARLY SIGNALS OF EFFICACY IN
IMPROVING BLOOD COUNTS
    * PLURISTEM THERAPEUTICS INC - THIRD AND FINAL COHORT WILL
BE
COMPRISED OF 15 PATIENTS

Source text for Eikon:  ID:nGNX8ywQyN 
Further company coverage:  PSTI.O 

 (Reuters.Briefs@thomsonreuters.com)